Lecture notes for medical students

1. Tips on using my ppt.
1. You can freely download, edit, modify and put your
name etc.
2. Don’t be concerned about number of slides. Half the
slides are blanks except for the title.
3. First show the blank slides (eg. Aetiology ) > Ask
students what they already know about ethology of
today's topic. > Then show next slide which enumerates
aetiologies.
4. At the end rerun the show – show blank> ask questions >
show next slide.
5. This will be an ACTIVE LEARNING SESSION x
three revisions.
6. Good for self study also.
7. See notes for bibliography.

2. Introduction & History.

3. Introduction & History.
• Unlike other malignancies the incidence
has dropped.
• Refregeration ?

4. Etiology

5. Etiology
• Idiopathic
• Congenital
• Traumatic
• Infections /Infestation
• Autoimmune
• Neoplastic (Benign/Malignant)
• Degenerative

6. Etiology:Causes
• Partial gastrectomy
• Helicobacter pylori
• A family history of stomach cancer is a
further risk factor in the disease.
• People with blood type A also have an
increased risk.
• Pernicious anemia
• Diet deficient in fresh fruits and vegetables
and rich is smoked fish or meat and poorly
preserved foods

7. Etiology:Premalignant leisons
Hereditary syndromes
• Hereditary diffuse gastric cancer (HDGC)
• Lynch syndrome (hereditary nonpolyposis
colorectal cancer)
• Familial adenomatous polyposis (FAP)
• Juvenile polyposis syndrome
• Peutz-Jeghers syndrome

8. Pathophysiology
•

9. Pathophysiology
• Correa’s cascade- Helicobacter
pylori infection >chronic non-atrophic
gastritis > atrophic gastritis>intestinal
metaplasia>dysplasia.

10. Pathology
•

11. Pathology
• Macroscopic appearance.-
– Ulcerative
– Polypoid
– Scirrhous (ie, diffuse linitis plastica)
– Superficial spreading
– Multicentric
– Barrett ectopic adenocarcinoma.

12. Pathology
• Macroscopic appearance.-

13. Pathology
• Macroscopic appearance.-

14. Pathology
• Adenocarcinoma - 90-95%
• Lymphomas - 1-5%
• Gastrointestinal stromal tumors (formerly
classified as either leiomyomas or
leiomyosarcomas) - 2%
• Carcinoids - 1%
• Adenoacanthomas - 1%
• Squamous cell carcinomas - 1%

15. Clinical Features

16. Clinical Features
• Demography
• Symptoms
• Signs
• Prognosis
• Complications

17. Demography

18. Demography
• Once the second most common cancer
worldwide, stomach cancer has dropped to
fourth place, after cancers of the lung,
breast, and colon and rectum.
• Highest in Asia and parts of South America
and lowest in North America.
• Japan most common cancer site in males.
• Most patients are elderly at diagnosis. The
median age for gastric cancer in the United
States is 69 years

19. Symptoms
Early disease has no associated symptoms; Most symptoms
of gastric cancer reflect advanced disease

20. Symptoms
Early disease has no associated symptoms; Most symptoms
of gastric cancer reflect advanced disease
• Indigestion
• Nausea or vomiting
• Dysphagia
• Postprandial fullness
• Loss of appetite
• Melena
• Hematemesis
• Weight loss
• Lump in abdomen

21. Late Symptoms
• Pathologic peritoneal and pleural effusions
• Obstruction of the gastric outlet
gastroesophageal junction, or small bowel
• Bleeding in the stomach from esophageal
varices or at the anastomosis after surgery
• Intrahepatic jaundice caused by
hepatomegaly
• Extrahepatic jaundice
• Weight loss resulting from starvation or
cachexia of tumor origin

22. Signs

23. Signs
All physical signs are late events.
• palpable enlarged stomach with succussion
splash;
• Hepatomegaly
• Periumbilical metastasis (Sister Mary Joseph
nodule
• Pallor from anemia
• Enlarged lymph nodes
– Virchow nodes (ie, left supraclavicular)
Troisier sign
– Irish node (anterior axillary).
– Blumer shelf (ie, shelflike tumor of the anterior

24. Signs
• Paraneoplastic syndromes such as
dermatomyositis, acanthosis nigricans, and
circinate erythemas are poor prognostic
features.
• Other associated abnormalities include
peripheral thrombophlebitis Troussaau sign
and microangiopathic hemolytic anemia.
•

25. Staging
TNM classification system

26. Staging
TNM classification system
• TX - Primary tumor
(T) cannot be assessed
• T0 - No evidence of
primary tumor
• Tis - Carcinoma in
situ, intraepithelial
tumor
• T1 - Tumor invades
lamina propria,
muscularis mucosae,
or submucosa
• T2 - Tumor invades
muscularis .
• T3 - Tumor penetrates
subserosal connective
tissue without invasion
of visceral peritoneum
or adjacent structures
• T4 - Tumor invades
serosa (visceral
peritoneum) or
adjacent structures

27. Staging
TNM classification system
Regional lymph nodes
• NX - Regional lymph nodes (N) cannot be
assessed
• N0 - No regional lymph node metastases
• N1 - Metastases in 1-2 regional lymph nodes
• N2 - Metastases in 3-6 regional lymph nodes
• N3 - Metastases in 7 or more regional lymph
nodes

28. Staging
TNM classification system
Distant metastasis
• M0 - No distant metastasis
• M1 - Distant metastasis

29. Staging
TNM classification system
• Stage 0 - Tis, N0, M0
• Stage IA - T1, N0, M0
• Stage IB - T2, N0, M0; or T1, N1, M0
• Stage IIA - T3, N0, M0; T2, N1, M0; or T1, N2,
M0
• Stage IIB - T4a, N0, M0; T3, N1, M0; T2, N2,
M0; or T1, N3, M0

30. Staging
TNM classification system
• Stage IIIA - T4a, N1, M0; T3, N2, M0; or T2, N3,
M0
• Stage IIIB - T4b, N0, M0; T4b, N1, M0; T4a, N2,
M0; or T3, N3, M0
• Stage IIIC - T4b, N2, M0; T4b, N3, M0; or T4a,
N3, M0
• Stage IV –M1, Any T, any N

31. Classification

32. Classification
• Adenocarcinoma of the stomach is
subclassified according to histologic
description
– Tubular
– Papillary
– Mucinous
– Signet-ring cells
– Undifferentiated lesions
•

33. Classification
• In about 5% of primary gastric cancers, a
broad region of the gastric wall or even the
entire stomach is extensively infiltrated by
malignancy, resulting in a rigid thickened
stomach, termed linitis plastica. Patients
with linitis plastica have an extremely poor
prognosis.

34. Classification
• The Lauren system classifies gastric cancer
pathology
– Type I (intestinal)
– Type II (diffuse).

35. Prognosis

36. Prognosis
• Stage 0 - Greater than 90%
• Stage Ia - 60-80%
• Stage Ib - 50-60%
• Stage II - 30-40%
• Stage IIIa - 20%
• Stage IIIb - 10%
• Stage IV - Less than 5%.

37. Investigations
• Laboratory Studies
– Routine
– Special
• Imaging Studies
• Tissue diagnosis
– Cytology
• FNAC
– Histlogy

38. Investigations

39. Investigations
Laboratory Studies
• CBC: anemia
• Electrolyte panels
• Liver function tests
• Tumor markers such as CEA and CA 19-9:
Elevated CEA in 45-50% of cases; elevated
CA 19-9 in about 20% of cases
• HER2-neu testing if metastatic
adenocarcinoma is documented or
suspected

40. Diagnostic Studies

41. Diagnostic Studies
Imaging Studies
• X-Ray Chest
– Double-contrast upper GI series and barium
swallows.
• USG
• CT / PET CT
• Angiography
• MRI
• Endoscopy*/ EUS
• Nuclear scan

42. Diagnostic Studies
Imaging Studies
• Finding early gastric cancer

43. Differential Diagnosis

44. Differential Diagnosis
• Acute Gastritis
• Atrophic Gastritis
• Bacterial
Gastroenteritis
• Chronic Gastritis
• Esophageal Cancer
• Esophageal Stricture
•
• Esophagitis
• Malignant Neoplasms
of the Small Intestine
• Non-Hodgkin
Lymphoma
• Peptic Ulcer Disease
• Viral Gastroenteritis

45. Operative Therapy

46. Operative Therapy
• Tis, or T1-- Endoscopic mucosal resection
or surgery are the standard treatment
options
• Stage IB to IIIC(resectable tumors)
preoperative chemotherapy or
chemoradiotherapy followed by surgery.
• Postoperative chemoradiation or
chemotherapy is indicated for patients who
have undergone primary D2 lymph node
dissection

47. Minimally invasive Therapy

48. Minimally invasive Therapy
• Endoscopic resection for early-stage
cancers

49. Palliative Chemotherapy

50. Palliative Chemotherapy
• For patients with unresectable tumors,
palliative fluoropyrimidine- or taxane-based
chemoradiotherapy or chemotherapy

51. Operative Therapy

52. Operative Therapy
• Total gastrectomy
• Esophagogastrectomy
• Subtotal gastrectomy
• Lymph node dissection: Controversy exists
regarding extent of dissection; the National
Comprehensive Cancer Network (NCCN)
recommends D2 dissections over D1
dissections.

53. Chemotherapy, Targeted therapy

54. Chemotherapy, Targeted therapy
• Platinum-based combination chemotherapy:
– epirubicin/cisplatin/5-FU
– docetaxel/cisplatin/5-FU
– rinotecan and cisplatin
– oxaliplatin and irinotecan
• Trastuzumab(Herceptin)with cisplatin and
capecitabine or 5-FU in HER-2neu +
• Ramucirumab

55. Neoadjuvant, adjuvant, and palliative
therapies

56. Neoadjuvant, adjuvant, and palliative
therapies
• Neoadjuvant chemotherapy
• Intraoperative radiotherapy (IORT)
• Adjuvant chemotherapy (eg, 5-FU)
• Adjuvant radiotherapy
• Adjuvant chemoradiotherapy
• Palliative radiotherapy
• Palliative-intent procedures (eg, wide local
excision, partial gastrectomy, total
gastrectomy, simple laparotomy,
gastrointestinal anastomosis, bypass)

57. Prevention

58. Prevention
• Screening
• Control environmental factors
• Management of precancerous conditions

59. Screening

60. Screening
• Photofluorography
• Endoscopy
• Serum pepsinogen testing
• Helicobacter pylori antibody testing.

61. Control environmental factors

62. Control environmental factors
• Smoking
• Diets high in salt, smoked foods, salted fish
and meat, and pickled vegetables
• Helicobacter pylori infection
• Previous gastric surgery
• Pernicious anemia
• Adenomatous polyps
• Chronic atrophic gastritis
• Radiation exposure

63. Management of precancerous
conditions

64. Management of precancerous
conditions
• Magnification chromoendoscopy or narrow-
band imaging (NBI) endoscopy
• Biopsies
• Endoscopic surveillance every 3 years
• H pylori infection is present>eradication
• Polyps with high-grade dysplasia that
cannot be removed, or invasive cancer
detected on biopsy should be referred for
gastrectomy.

65. Management of precancerous
conditions: HDGC
• Mutations of the E-cadherin gene (CDH1)
• Prophylactic gastrectomy (without a D2
lymph node dissection) between the ages of
18 and 40 for asymptomatic carriers with a
family history of HDGC
• Women with CDH1 mutations are at
increased risk for breast cancer and should
be followed similar
to BRCA1/ BRCA2 mutation carriers

66. Breast Cancer Prevention
for BRCA1and BRCA2 Mutation Carriers

67. Breast Cancer Prevention
for BRCA1and BRCA2 Mutation Carriers
• For women who carry a mutation in
the BRCA1 or BRCA2 genes, the risk of
breast cancer by age 70 years is
approximately 65% and 45%,
respectively. Breast cancer prevention for
these women has predominantly focused on
surgical strategies, such as bilateral
mastectomy and endocrine ablation by
premenopausal bilateral salpingo-
oophorectomy (BSO).

68. Breast Cancer Prevention
for BRCA1and BRCA2 Mutation Carriers
• Who decline bilateral mastectomy, or
choose to delay it until they are older,
tamoxifen should be considered,

69. Get this ppt in mobile
1. Download Microsoft
PowerPoint from play
store.
2. Open Google assistant
3. Open Google lens.
4. Scan qr code from
next slide.

71. Get this ppt in mobile
1. Download Microsoft
PowerPoint from play
store.
2. Open Google assistant
3. Open Google lens.
4. Scan qr code from
next slide.

72. Get this ppt in mobile

73. Get my ppt collection
• https://www.slideshare.net/drpradeeppande/
edit_my_uploads
• https://www.dropbox.com/sh/x600md3cvj8
5woy/AACVMHuQtvHvl_K8ehc3ltkEa?dl
=0
• https://www.facebook.com/doctorpradeeppa
nde/?ref=pages_you_manage